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Objective: To evaluate the accuracy of the Acute Physiology and Chronic 
Health Evaluation (APACHE) II prognostic scoring system when applied to 
human immunodeficiency virus (HIV) seropositive patients (with or 
without the acquired immunodeficiency syndrome (AIDS)) in the Medical 
Intensive Care Unit (MICU). 
Methods: The medical records of all HIV-positive patients who were 
discharged from the Yale-New Haven Hospital MICU between October 1, 1986 
and September 30, 1991 were retrospectively reviewed and clinical and 
laboratory data, including variables needed for APACHE II scoring, were 
collected. Patients were assigned to disease categories using pre-determined 
algorithms when documented clinical decisionmaking was unclear. 
Results: Records from 161 separate MICU discharges met the criteria for the 
study. APACHE II greatly underestimated mortality among patients with 
pneumonia (n=44) (28.5% estimated (E) vs. 50.0% observed (O), p < .005). In 
the group of patients with pneumonia, APACHE II accurately predicted 
mortality in patients with Pneumocystis cnrinii pneumonia (n=26) (28.2% (E) 
vs. 34.6% (O)) but underestimated mortality in patients with pneumonia of 
other or unknown etiology (n=18) (28.9% (E) vs. 72.2% (O), p < .005). In all 
other patients (patients without pneumonia) (n=117), APACHE II correctly 
estimated mortality (38.1% (E) vs. 41.9% (O')). In patients admitted to the 
MICU with a diagnosis of infection (pneumonia or sepsis), a total lymphocyte 
count (TLC) < 200 was a strong predictor of mortality. In all other patients 
(without pneumonia or sepsis), TLC was not associated with outcome. 

2 
Conclusion: The APACHE II prognostic scoring system is an effective method 
of stratifying a general HIV-positive MICU patient population in respect to in- 
hospital mortality, but it is not accurate when applied to a significant 
proportion of our population, HIV-positive patients with pneumonia, 
particularly non-Pneumocystis carinii pneumonia. The reason for APACHE 
II's underestimation of mortality is multifactorial. It is likely to be due, at 
least partially, to (1) absence of adequate risk adjustment for severity of 
immunologic suppression; (2) lack of precisely defined decisionmaking 
algorithms to aid in the assignment of disease categories; and (3) a significant 
proportion of HIV-positive patients with pneumonia of unknown etiology 
who may be uniquely resistant to treatment. The use of TLC as an additional 
risk factor may improve predictive accuracy of ICU risk adjustment models 
for use in HIV-positive patients with diagnoses of infection. 
IL INTRODUCTION 
Beginning in the mid-1980's, the human immunodeficiency virus 
(HIV) and the acquired immunodeficiency syndrome (AIDS) have had an 
enormous impact on the American health care system and particularly on the 
field of intensive care medicine. In 1990, there were an estimated one million 
people infected with HIV in the United States.1 Of these one million people, 
it has been projected that nearly 205,000 will have frank AIDS in 1993 and 
nearly 246,000 in 1994.2 Many of these people with AIDS will need to be 
admitted to an intensive care unit at some time during their illness. Using 
an estimate that the cost of treating all people infected with HIV will increase 
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roughly 20% per year, it has been projected that $10.4 billion will be spent 
treating all people infected with HIV in 1994 alone.2 
Because AIDS has spread so rapidly and has affected such a great 
proportion of the population, much research has been focused on elucidating 
the pathophysiology of the human immune system and the role of 
opportunistic infections in immunocompromised hosts. In addition to 
promoting basic science research, HIV infection and the "AIDS epidemic" 
have led to greater discussion about the ethical dilemmas surrounding 
quality of life decisions,3'14 and the aggressive medical treatment of patients 
with serious and/or terminal illnesses.15'13 The healthcare system, and 
society as a whole, is faced with difficult and interconnected ethical and 
financial decisions. Physicians are being forced to do cost-benefit analyses in 
addition to making the medical decisions for which they were trained. The 
sort of decisions being made are variations on one simple question: "Is the 
result worth the cost?" In other words, do the medical outcomes justify the 
financial resources being spent? 
This question must be considered in all medical settings and involving 
all types of medical/financial decisions, ranging from state-funded childhood 
immunization programs to organ transplant surgery. To answer these 
questions, patient outcomes must be assessed and analyzed. Until recently, 
however, the means to do this analysis have been lacking. Although the raw 
data (mortality rates, nosocomial infection rates, surgical complication rates, 
etc.) have been available, medical outcome analysis had proved to be difficult 
to analyze since medical outcomes are dependent on a wide array of variables. 
Medical outcomes are dependent not only upon the quality of medical care 
but also upon other factors, including comorbid illnesses, access to care, 
patients' extent of acute illness, and etiology of disease. 
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One area of medicine in which cost-benefit discussions and medical 
outcome analysis has become common has been in the intensive care setting. 
In intensive care units (ICU's), prognostic stratification systems have been 
developed to better analyze medical outcomes. The prognostic stratification 
systems adjust for the variability of patient "case mix." In other words, these 
systems are means of performing risk adjustment related to medical 
outcomes. By accounting for varying degrees of patient "risk," these 
prognostic systems allow more accurate outcome comparisons to be made and 
facilitate cost-benefit analyses. 
The most widely accepted system of risk adjustment in the ICU setting 
is the Acute Physiology and Chronic Health Evaluation (APACHE) II 
prognostic scoring system. Presently, however, APACHE II has not been 
thoroughly evaluated in patients who are HIV positive or who have AIDS. 
Thus, healthcare professionals are lacking the tools necessary to effectively 
analyze medical outcomes in HIV-positive patients. Because a reliable 
research tool is needed for outcome analysis in the increasing numbers of 
HIV-positive patients, an evaluation of APACHE II's ability to perform risk 
adjustment in HIV-positive patients was undertaken. Before discussing the 
current study and the recent literature pertaining to the application of 
APACHE II to an HIV-positive patients population, understanding the 
pertinent issues will be enhanced by briefly reviewing the field of prognostic 
stratification and the development of the original APACHE and APACHE II 




Perhaps the easiest way to introduce the concept of prognostic 
stratification is to consider the numerous ways in which it is used by 
everyone in everyday life, on a minute-to-minute basis. When an 
automobile driver accelerates at a green light, when a baseball outfielder shifts 
position for a left-handed batter, or when a diner orders a meal, prognostic 
stratification is actively, though usually without awareness, being used. In 
each of these "routine” daily circumstances, a decision is being made based on 
past experiences in similar situations. The driver realizes that in the past 
when he has been waiting at an intersection and the light has turned green, it 
has usually, if not always, been safe to accelerate and cross the intersection. 
The outfielder, probably with greater awareness of his mental processes, 
recognizes, based on past experience (either his own or communicated by 
others), that a left-handed batter is more likely to hit the ball toward right 
field, and consequently, it would be wise to shift his field position accordingly. 
The diner, preparing for a meal, remembers his own past dining experiences 
(or those experiences told to him by friends), and orders based on expectations 
of gustatory pleasure. In each of these circumstances, past experiences are 
used to modify or make decisions in the present with an anticipated future 
result. 
Despite being done unconsciously or with little thought, each of these 
hypothetical decisions is not simply based on vague, ill-defined recollections 
and remembrances. Each person makes a decision based on past experiences 
of similar circumstances or situations (a green light, a left-handed batter, or a 
cheeseburger) being associated with another occurrence (driving safety, a fly 
ball to right field, or enjoying one's meal). In effect, each decision is based on 
nothing more than past associations and the assumption that past 
associations will remain true and valid in the future. In other words, each 
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decision in "routine" daily life is based on calculated probabilities arrived at 
through past associations. 
Thus, prognostic stratification is the process in which entities 
(circumstances, occurrences, people, etc.) are placed into different strata based 
upon past associations and future prognosis. This can be restated: 
"Prognostic stratification is the process in which entities are placed into 
groups with similar predicted results or outcomes." 
Given the need in clinical medicine to base testing and therapy on 
evidence of improved outcomes, it is no suprise that prognostic stratification 
is used extensively in clinical medicine, and that medicine is, in fact, 
dependent upon prognostic stratification. All medical decisions implicitly 
utilize prognostic stratification. When a physician discerns "baseline risk," 
considers different treatments based on the "clinical course" of a disease, 
assigns cancer patients to different "stages," or chooses "appropriate" 
antibiotic therapy for a presumed infection, he or she is actively grouping 
(stratifying) patients according to outcome prediction (prognosis). 
As discussed by Feinstein,19 prognostic stratification has three general 
purposes in medicine: analytic, predictive, and explicative. In the first 
instance, prognostic stratification can be used to reduce the effects of a 
population's heterogeneity and "enhance the accuracy and efficiency of 
statistical analysis"11' in one of two ways. Prognostic stratification can allow 
for the avoidance of either false positive error or false negative error, and it 
can improve the efficiency of statistical comparison of population groups. 
False positive errors occur when "statistically significant" results are found 
which are solely caused by the heterogeneity of the compared population 
strata, not by true differences as measured by the test in question. Feinstein 
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gives the following example19 of false positive error and the use of prognostic 
stratification in avoiding this type of error: 
Suppose we found that a group of 100 men with disease D had a 10-year 
survival rate of 38%, whereas the rate was 62% for a group of 100 women with 
the same disease. We might conclude that the disease had distinctly different 
effects in men and women. 
Now suppose, however, that patients with this disease could be 
divided into a "good risk" prognostic stratum, with 80% 10-year survival, and a 
"poor risk" stratum with 20% 10-year survival. Suppose further that the male 
population contained 30 members from the good-risk stratum and 70 members 
from the poor-risk stratum, but that these distributions were exactly reversed 
in the female population. We would then find the following results for 10-year 
survival rates: 
Men Women Total 
Good Risk 24/30(80%) 56/70 (80%) 80/100(80%) 
Poor Risk 14/70(20%) 6/30(20%) 20/100(20%) 
Total 38/100(38%) 62/100(62%) 100/200(50%) 
On comparing results within the same prognostic strata, we would find 
that the disease had exactly the same effects in men as in women: 80% 
survival for good risks, and 20% survival for poor risks. Our original conclusion 
about the disparate effects of the disease in men and women would have been 
wrong because of the disproportionate distribution of the good-risk and poor- 
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risk strata in the male and female cohorts. The male cohort was composed of 
70% poor risks and 30% good risks, whereas the percentages were just the 
opposite in the cohort of women. 
Conversely, false negative errors occur when "statistically significant" results 
are not found (or are hidden) due to the heterogeneity of the compared 
population strata. 
Prognostic stratification improves the efficiency of statistical 
comparison by identifying "polar strata," (those members of a population 
who are either extremely likely or unlikely to attain the specific result being 
considered). If allowed to remain unidentified, members of the "polar strata" 
will mix in with the total population, thereby diluting the test's results and 
producing inefficient statistical comparison. In addition, the identification 
and separation of "polar strata" is especially important in the testing and 
analysis of therapeutic claims. For example, in investigating a new treatment 
for cancer, it is extremely difficult to prove that the new treatment is either 
effective or ineffective. Oftentimes, in order to produce statistically 
significant results, inordinately large (and financially constraining) 
population sample sizes must be employed. In this situation, a polar stratum 
is an ideal population to use as a test population because a polar stratum, by 
definition, is either extremely likely or unlikely to attain a specific result and, 
therefore, the predicted result will have a small calculated standard error and 
a narrow confidence interval (ranging between two standard errors below and 
above the mean). Consequently, by testing the new treatment on a polar 




The second general purpose of prognostic stratification is predictive. 
The manner in which prognostic stratification can "enhance confidence in 
the predictive decisions of clinical practice"19 has been mentioned but 
deserves to be discussed more thoroughly. One way in which prognostic 
stratification can improve predictive accuracy is by allowing clinicians to base 
current prognosis on the outcome of past patients who were in the same 
prognostic stratum as the present subject. Second, prognostic stratification 
can improve therapeutic decisionmaking by allowing physicians to choose 
treatments which have been tested and have proven results on patients with 
the same attributes as the present patient. This use of prognostic stratification 
is directly applicable to patient-specific decisionmaking concerning the 
initiation or withdrawal of life-sustaining or life-prolonging therapies. For 
example, extremely low birthweight infants with a zero percent survival 
probability usually will not have heroic therapy initiated. Third, the design of 
therapeutic trials can be refined by dividing the study population into 
distinctive prognostic strata prior to comparing tested treatments. This can be 
done to improve either randomized or nonrandomized trials and is 
especially important in nonrandomized trials when stratification is the main 
method available to reduce bias. 
A third use of prognostic stratification is "to demarcate observed 
phenomena in a manner that allow them to receive a scientific 
explication."19 In other words, prognostic stratification is useful for 
explaining the variability or variance of observed outcomes. With the 
current political and administrative emphasis on cost control and resource 
allocation (ICU utilization, nursing care staffing, patient triage decisions), this 
ability of prognostic stratification to explain the variance of outcome 
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measures is becoming especially important and useful in health care research, 
decisionmaking, and the evaluation of medical care quality. 
Prognostic stratification is able to explain the variance of outcomes by 
what has been termed "risk adjustment" or "case-mix adjustment." By 
dividing a heterogeneous patient population into groups (strata) with similar 
medical expectations (prognoses), prognostic stratification can reduce the 
uncertainty inherent in comparing outcome measures and allow a more 
meaningful comparison and explanation of observed outcomes. Without 
prognostic stratification, any differences in target events (ie., observed 
mortality rates, infection rates, etc.) can not be ascribed to actual differences in 
the process being measured. "[T]he compared maneuvers may appear to give 
different results; but the real difference may arise only from disproportions in 
the strata that constitute the cohort."20 
Outcome comparisons can be made at three organizational levels: 
between individuals, between groups of people, or between institutions. 
Temporal comparisons can also be made: comparing outcome data from the 
same individual, group, or institution during different time periods. 
Although some outcome measures are more commonly analyzed in specific 
situations (ie., mortality rates at an interinstitutional level, surgical success 
rates at an individual level), any one outcome measure can be analyzed at any 
organizational level, and the inherent uncertainty of all outcome 
comparisons is reduced by means of prognostic stratification. In fact, outcome 
analysis is virtually dependent upon prognostic stratification for the 
meaningful interpretation of results. 
The most common method of using prognostic stratification for the 
explication of outcome variance involves the development of prognostic 
scoring systems. These scoring systems can be and have been applied to a 
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variety of clinical conditions (discussed below). Despite the varying 
applications of these systems, they are all generally predicated on the same 
analytic formulations and are, consequently, very much alike. The analytic 
model which is followed is based on mathematical functions called additive 
value functions. Though a detailed analysis of additive value functions is 
beyond the scope of this paper, a short description of the foundation of these 
functions is worthwhile. 
Additive value functions, as discussed by Krischer,21 are special 
instances of mathematical formulae designed to quantify the relative 
importance that one attribute makes toward a general condition. In the 
health sciences, they are generally expressed in the form of an equation: 
V (Xi, X2.Xn) = V! (X]) + V2 (X2) + ... + Vn (Xn) 
where V is the prognostic score, X], X2, ..., Xn is a list of medical attributes that 
describe a person, and Vi, V2, ..., Vn are numerical descriptions of the relative 
importance or "weight" of each attribute. In terms of clinical prognostic 
stratification, additive value functions are designed to quantify the relative 
importance that each medical attribute makes toward general clinical 
prognosis. The form of this equation implies one important point. Namely, 
that each medical attribute included in the equation has a contribution to the 
formulation of medical prognosis, and is independent of the contributions 
made by the other medical attributes. 
One specific type of prognostic scoring system has been termed a 
severity of illness index. Like all prognostic scoring systems, severity of 
illness indices strive to group patients based on known attributes, and are 
analytically formulated on additive value functions. Severity of illness 
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indices are becoming increasingly popular in medical care for two reasons. 
First, the capacity to do the complex data analysis required by sophisticated 
severity of illness index software has increased dramatically during the last 
decade. And second, as political and economic attention has been 
increasingly focused on the current "health care crisis"in the United States, 
more data has been necessary for outcome comparisons. In keeping with the 
growing emphasis on outcome comparisons and "case-mix" data needed for 
such comparisons, severity of illness indices will be the focus of the 
remainder of this paper. 
Because severity of illness indices are a specific class of prognostic 
scoring system and are based on additive value functions, an obvious 
question arises concerning the formulation of indices: "How are the specific 
medical attributes (Xi ... Xn) and their relative importance (V] ... Vn) 
determined?" There are basically two methods to accomplish this task. One 
is to base the determination on clinical judgement; the other is to base the 
determination on statistical methods of analysis. Oftentimes, a severity of 
illness index will be created based upon clinical judgment, and later refined 
based upon statistical analysis. 
As reviewed in a report by the Institute of Medicine,22 three methods 
of formulating group judgment exist. The three methods are extremely 
similar in that they all use subjective and arbitrary assessments to form the 
basis of their decisions. They only differ on the manner in which the final 
group judgment is formulated. One method, the Delphi technique, arrives at 
its final formulation based a survey process of isolated, non-interacting, 
participants. The survey process elicits anonymous opinions from members 
of a selected expert group by formal questionnaire or individual interview. 
Summarized anonymous feedback is then provided to the group members 
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and opinions may again be elicited. The group response is formulated by 
aggregation of the individual opinions during the final round of questioning. 
The major advantage of the Delphi technique is that the participants are not 
in direct contact with one another, and, thus, "variables of professional status 
and personality have little chance to influence opinions as they might in face- 
to-face meetings...."22 Conversely, the major disadvantage of the Delphi 
technique is that the opportunity for the clarification of ideas among 
participants is lacking. 
Nominal group technique (NGT), differs from the Delphi technique in 
that the participants are not isolated from one another. Using NGT, 
participants express their opinions anonymously (either by writing or by 
computer terminal), and the opinions are considered by the group. 
Clarification of opinions may be given (also anonymously). Further rounds 
of iteration and clarification of opinions may be used as needed. The final 
formulation of group judgment is established by anonymous voting or 
ranking. The advantage of NGT, like the Dephi technique, is that effects of 
personal status and group hierarchical structure are minimized. However, 
NGT is superior over the Delphi technique in that it allows for the 
clarification of ideas among participants. 
The third method of arriving at group judgment is the consensus 
method. The hallmark of the consensus method is its reliance on open 
discussion among participants who know one another. Consensus 
conferences, employed by the National Institutes of Health, are characterized 
by an initial presentation of information, followed by open discussion, then 
the drafting of consensus answers, further discussion and comments about 
the consensus answers, and incorporation of the comments in a final 
consensus statement. Obviously, the consensus method does not limit the 
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influence of social, personal, or hierarchical factors on the formulation of the 
final group judgment. However, it may encourage discussion to a greater 
extent than NGT. 
In contrast to the use of group judgment, methods of statistical analysis 
use objectively derived information as the basis for the inclusion of attributes 
and their relative importance within the severity of illness index. The 
relevant information is derived from multivariable analysis to determine 
"statistically significant" associations between attributes and outcomes. After 
these determinations are made, statistically significant variables are included 
within the index, with their relative importance correlated to the degree of 
their statistical significance. The analysis is most commonly done by one of 
two methods: either multiple logistic regression or by proportional hazards 
regression (also known as Cox regression). Although a detailed description of 
these methods of statistical analysis are beyond the scope of this paper, they 
are covered in standard textbooks on statistics and have been thoroughly 
discussed in a recent journal article).23 
Though statistical analysis is the more superficially credible method 
(due to its mathematical rigor) in the development of severity of illness 
indices, some of the most widely accepted indices were developed using 
clinical judgment as the sole means of deriving the indices' formulations. 
One of the most widely recognized and used severity of illness indices is the 
Apgar Score. This index was developed in 1953 for the evaluation of 
newborn infants using subjective clinical judgment to create the 
mathematical formulation of the index. Another clinically derived index 
which has attained broad acceptance and use is the Glascow Coma Score 
which was designed to quantify degree of brain injury and improve 
prognostic accuracy in affected patients. 
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Beginning in the early 1970's and continuing through the 1980’s, as 
computer data analysis capacity increased and as the field of health care 
administration and research increasingly focused attention on the need for 
more reliable and objective means of analyzing health care outcomes, greater 
numbers of severity of illness indices were developed. Some indices were 
created for patients with specific diseases (burns, liver disease, schizophrenia, 
gastrointestinal hemorrhage, sepsis, scleroderma, drug overdose, acquired 
immunodeficiency syndrome, etc.). This has been evident especially 
concerning cardiac disease.24*30 Other indices have been designed specifically 
for certain patient groups. Patients with injuries from trauma and, in 
particular, automobile-related trauma have been the subject of many severity 
of illness indices (Figure l).31*37 
Figure 1: Early Trauma Indices 
Abbreviated Injury Scale (1971)31 
Trauma Index (1971 )32 
Comprehensive Injury Scale (1972)33 
Injury Severity Score (1974)34 
Modified Trauma Index (1974)33 
Triage Index (1974)'3^ 
Estimated Survival Probability Index (1978)37 
As briefly mentioned before, one area of health care in which health 
care researchers have fashioned numerous severity of illness indices in the 
intensive care unit (ICU) (Figure 2).33-43 This is so for numerous reasons. For 
one, intensive care units (ICU’s) are increasingly used as the treatment setting 
of choice for critically ill patients. Beginning in the 1960’s as hospital centers 
for emergency cardiac care, ICU’s have spread rapidly. By the mid-1970's, as 
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prognostic scales were proliferating, it was reported that seven out of every 
one thousand patients were transferred to an ICU for specialized care, and it 
was projected that nationally over seven million patient days were spent in 
ICU's annually.39 
Figure 2: Intensive Care Treatment Indices 
Therapeutic Intervention Scoring System (1974)3<s 
Condition Index Score (1981 )39 
Acute Physiology and Chronic Health Evaluation (APACHE) (1981 )49 
Simplified Acute Physiology Score (1984)41 
Mortality Prediction Model (1985)43 
APACHE 11 (1985)43 
Organ System Failure Based Model (1991)44 
APACHE III (1991 )45 
Second, ICU’s are the most costly site of medical care because they are 
the main locus in which acute, technologically advanced and expensive care 
is given. Heroic, life-sustaining treatment is readily available and is often 
used in ICU’s to keep patients alive while in the midst of their acute illness. 
This fact, coupled with the large volume of patients who are treated in ICU’s, 
accounts for the exponential growth of ICU expenditure. In 1992, intensive 
care services cost approximately 62 billion dollars and accounted for nearly 8% 
of projected national health care spending46 and approximately 1% of the 
United States' GNP.47 Because of the vast quantities of money being spent in 
ICU's, it became imperative that cost-efficient diagnosis and treatment plans 
be developed through risk adjusted outcome assessment. 
A third reason that intensive care was well suited for prognostic 
stratification research was that ICU outcomes were known to vary widely 
between different ICU's, but little was known as to the cause of the variation. 
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One review article reported mortality rates in surgical ICU's to range from 2% 
to 44%.4^ With the tools available in the late 1960’s and early 1970's, it was 
impossible to ascertain whether this outcome variation was due to differences 
in therapeutic efficiency (the quality of the medical care) or the differences in 
patient case mix (the degree of initial severity of illness and comorbidity). 
Fourth, intensive care was (and still is) characterized by a great degree 
of patient monitoring, laboratory use, and the routine daily collection and 
recording of a large amount of detailed clinical information. Consequently, 
researchers interested in medical outcome analysis had a large amount of 
readily available data with which to develop more sophisticated predictive 
models to measure patient case mix. 
Consequently, due to the combination of these four characteristics of 
intensive care medicine (a large volume of patients, an exponentially 
increasing use of financial resources, great variance in medical outcomes, and 
readily available clinical and laboratory data), medical outcome research was 
focused on intensive care from an early date. In this setting, many research 
tools were developed to allow a more meaningful evaluation or analysis or 
intensive care data. Many prognostic scoring systems and severity of illness 
indices were developed with the purpose of explaining some of the variance 
known to exist in intensive care outcomes and allowing risk-adjusted 
comparisons of medical outcomes. 
APACHE 
One index which was designed to help explain the variance of 




(APACHE) prognostic scoring system.40 This prognostic system was 
developed by William A. Knaus, M.D. and colleagues at the George 
Washington University Medical Center. In 1978, with a grant by the U.S. 
Health Care Financing Administration (HCFA), Knaus et. al. began 
developing APACHE to provide "an improved method for estimating the 
pretreatment risk of death of acutely ill hospitalized patients...."44 In other 
words, one of the purposes of the APACHE system was to provide a means to 
improve clinical prognostic accuracy. 
In addition to its predictive function, APACHE was designed with an 
explicative purpose. APACHE was designed to explain outcome variance 
(differences in in-hospital mortality rates) by "adjusting" for the patients' 
initial composite severity of illness. Thus, APACHE could provide an 
objective means to assess patient care outcomes at different institutions or 
within the same institution at different points in time or among different 
patient groups. Knaus and his colleagues felt that APACHE could have 
analytic use by improving "the ability of nonrandomized study designs to 
produce convincing evidence of efficacy."40 The essence of the APACHE 
severity of illness index was that it could objectively quantify the degree of 
patient illness, and thus, could provide "an answer to the nagging question of 
most nonrandomized studies: 'Were the two patient groups similar?'"40 
The conceptual approach of APACHE toward measuring a patient's 
severity of illness included two areas of assessment: a physiological score 
representing acute illness and a preadmission health evaluation indicating 
health status before acute illness. The acute physiology score (APS) was 
calculated by measuring the most abnormal value of each of thirty-four 
physiologic variables (blood pressure, heart rate, serum pH, serum sodium, 
etc.) during the first thirty-two hours of ICU admission. Each variable and its 
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relative influence on the APS were determined by consensus methods. The 
variables were chosen to represent a derangement in one of the body's seven 
major physiological systems (neurological, cardiovascular, respiratory, 
gastrointestinal, renal, metabolic, and hematological) and were assigned a 
weight ranging from zero to four depending on the degree of derangement: 
the more abnormal the measured variable, the greater the weight assigned. 
Because the APS was solely the sum of the measured variables, it followed 
that the more abnormal the measured variables, the higher would be the 
APS, thus representing a more acutely ill the patient. 
The second area of assessment, the preadmission health status, was 
included within APACHE so as to differentiate patients with similar acute 
physiology, yet with different abilities to "fight off death" and recover. In the 
original APACHE this assessment was based on the patient's functional 
status, productivity, and degree of medical attention sought six months prior 
to admission. The patient was assigned a letter designation (A, B, C, or D) to 
correspond to a physiologic reserve ranging from good prior health (A) to 
severe restriction of activity due to disease (D). 
Although APACHE was a fairly reliable means of stratifying ICU 
patients according to their severity of illness and risk of subsequent hospital 
death, APACHE proved to be too complex for routine clinical use.49 
Consequently, Knaus and colleagues reevaluated APACHE, made some 
necessary changes, and called the modified system APACHE II (Figure 3). 
Whereas the original APACHE score was based on two components (the APS 
and the preadmission health status), the APACHE II score was the numerical 
sum of three components: 
APACHE II Score = APS + Age points + Chronic Health points. 
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In the area of assessing the degree of acute illness, the APACHE acute 
physiology score was judged to incorporate too many physiologic variables, 
some of which were not routinely measured (serum osmolarity, serum lactic 
acid, skin anergy testing, etc.) or added little explanatory power (ie., serum 
glucose, urinary output, albumin,).43 By using a combination of consensus 
methods (based on clinical judgment) and methods of statistical analysis, the 
thirty-four APACHE variables were reduced to twelve to form the APACHE II 
APS. Another change to the APS consisted of revising the weighting system. 
Although most variables were weighted in the same manner as before (from 
zero to four, with a weight of four signifying the greatest physiologic 
derangement) three variables were given different calculation parameters, 
namely, serum creatinine during acute renal failure, the Glascow coma score 
as a measure of neurologic function, and oxygenation assessment was 
quantified with consideration of inspired oxygen concentration (FiCb). As 
well, in a slight change from the original APACHE system, the recorded value 
of each physiologic variable was based on the most abnormal reading during 
the patient’s first twenty-four (instead of thirty-two) hours in the ICU. 
The assessment of prior health status, though conceptually the same as 
in the original APACHE, was more specifically defined. The new system's 
prior health assessment considered patient age (a graded scale ranging from 
zero to six, with advanced age being accorded more points), and chronic 
health evaluation. The chronic health evaluation was based on both chronic 
organ system insufficiency (either hepatic, cardiovascular, respiratory, renal, 
or immunologic) and operative status (nonoperative, emergency 
postoperative, or elective postoperative). 
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The major modification incorporated into the APACHE system was a 
classification of disease process. This was done with the realization that 
patients with equal acute physiologic derangement but with different 
pathophysiologic processes are clinically expected to have unequal mortality 
risks. As an example: two patients, both with identical pathophysiologic 
abnormalities (poor oxygenation and acidemia) are admitted to the ICU for 
respiratory support. One patient is admitted due to asthma; the other due to 
an advanced lung neoplasm. Although their acute physiologic derangements 
are identical, these patients have significantly different probabilities of dying. 
Because the latter patient has a much more life threatening disease, his risk of 
death is much higher. In order to incorporate this reasoning, the modified 
APACHE assigned each patient to a diagnostic category and assigned each 
diagnostic category its own weighting used to predict mortality. 
The APACHE II scoring system retained the same conceptual 
framework of the original APACHE system in that each patient's total 
APACHE score was computed by summing the APS, the age points, and the 
chronic health points. The range of possible APACHE II scores is from zero to 
seventy-one with a higher score associated with a greater likelihood of death. 
At the time of original publication describing the APACHE II system, the 
highest actual patient score recorded was fifty-five. Although the APACHE II 
score could be used for patient classification and stratification within 
treatment groups, it alone could not be used to predict medical outcomes 
(death versus survival). The APACHE II score was only one factor used in 
the calculation of predicted mortality risk. 
APACHE II was able to prognosticate in-hospital mortality rates by 
incorporating disease process classification into its patient assessment. 
Specifically, APACHE II placed patients into one of fifty-three diagnostic 
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categories (twenty-nine being nonoperative, and twenty-four being 
postoperative) according to the reason for ICU admission. Each category was 
assigned a diagnostic category weight (DCW), and predicted risk of subsequent 
hospital death could be calculated by using the following multiple logistic 
regression equation : 
In (R/l-R)= -3.517+ .146 (APACHE II score)+ DCW + .603 {only if 
emergency postoperative}, 
where R is the risk of death. 
It should be noted that the APACHE II system of risk prediction, 
though based on an equation used to predict mortality risk for individual 
patients, was not designed to be used for individual patient risk prediction. 
The APACHE II was developed to predict mortality risk for groups of patients. 
(Individual patient prognosis was felt to be an unrealistic goal for two 
reasons: one, because of the great variation among individual patients in 
terms of hospital course and pre-existing disease, and two, because 
"physicians are ... reluctant to accept estimated probabilities as the basis of 
limiting or stopping treatment."40 (In order to maintain the accuracy of 
APACHE II, it was suggested that disease-specific mortality predictions must 
be derived on a minimum of fifty patients in each diagnostic category, with at 
least twenty patients in the least frequent outcome category.) Though not 
designed to substitute for clinical judgment regarding individual patient 
outcome prediction or treatment decisions, APACHE II could be used as a 
source of information for clinicians and as a tool for analysis of medical 
outcomes. As well, it should be realized that APACHE II was designed as a 
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means of prospective health assessment and risk stratification. Thus, 
APACHE II measurements (physiologic variable readings) and classification 
decisions (placement of patients into disease categories) were made on a real 
time basis without the advantage of hindsight. 
The APACHE II prognostic scoring system was validated in a study of 
5,815 ICU admissions at thirteen different hospitals.43 A direct relationship 
between APACHE II scores and observed hospital mortality rate was found to 
be statistically significant through the entire range of scores (greater APACHE 
II scores were associated with higher mortality rates). Direct cross-tabulations 
and multivariate techniques were used to compare the predictive power of 
APACHE II with the original APACHE system and examine the relative 
importance of the components of APACHE II. This analysis showed that 
APACHE II had better explanatory power than the original APACHE as 
measured by model chi-square, percent of cases correctly identified, R-squared, 
rank correlation between outcome and predicted probability, and area under 
ROC curve (Table 1). The overall correct classification rate (classifying 
patients as either predicted to die or predicted to survive) was eighty-six 
percent (using a predicted mortality cutoff point of 0.50) (Table 2). 
In general, APACHE II has been quite a success as is evident by its 
widespread use by other researchers. The APACHE II system has been 
incorporated into independent studies, in research related to both clinical 
decision-making and health policy.7>49 As well, in the clinical realm of 
medicine, hospitals have used APACHE II within their ICU’s as the basis for 
utilization and outcome-based quality management programs, and some 
foreign countries have even adopted APACHE II as the prognostic scoring 
system in all of their ICU’s.49 
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Table 1: Measures of Aggregate Explanatory Power 
APACHE* APACHE 11 
Model Chi-square 1537.1 1634.5 
R-squared .310 .319 
Rank correlation (between 
outcome and predicted probability) .730 .739 
Area under ROC curve .851 .863 
Data presented in "APACHE II: A Severity of Disease Classification System" by 
Knaus et. al. 





Sensitivity (%) 49.0 47.0 
Specificity (%) 97.3 94.9 
PPV (%) 79.4 69.6 
NPV (%) 90.0 87.9 
Correct (%) 88.8 85.5 
A cutoff of 0.50 was used to divide the two predicted groups. Calculated mortality risk 
> 0.50 implied predicted death; calculated mortality risk < 0.50 implied predicted 
survival. 
Data presented in "APACHE II: A Severity of Disease Classification System" by 
Knaus et. al. 
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However, despite widespread utilization of APACHE II by independent 
research groups, there still exists some controversy about its role in case-mix 
risk adjustment, severity of illness stratification, and mortality prediction. 
There have been both prospective and retrospective studies of APACHE II's 
utility when applied to specific patient groups or as compared to other 
prognostic scoring systems. APACHE II has been studied in regard to patients 
receiving total parenteral nutrition,50 patients with cardiogenic pulmonary 
edema,51 with hematologic malignancies,52 with perforated ulcers,55 with 
acute pancreatitis,54 with breast cancer,55 after cardiac arrest,56 with acute 
trauma,57 with intra-abdominal abcesses,58 and (as will be discussed below) in 
patients with acquired immunodeficiency syndrome (AIDS).59'62 Several 
studies highlight APACHE II's lack of advantage over clinical judgment in 
terms of predictive accuracy,63'65 while another study brings attention to the 
lead-time bias (caused by measuring patients attributes at varying times, 
including after initiation of therapy) inherent in the APACHE II system.66 
One research group documented APACHE II's inaccuracy in predicting 
surgical ICU parameters such as length of stay and total hospital costs,67 
though this should not be suprising since APACHE II was designed to predict 
and explain mortality rates, not utilization measures. 
Although these numerous publications have pointed out APACHE II's 
failings, they are, at the same time, a reference to APACHE II's strengths as a 
prognostic scoring system and act as testimony to the importance APACHE II 





Prognostic stratification in patients with AIDS or HIV seropositivity 
Many publications concerning patients with AIDS have focused on the 
relationship of patient attributes (CD4+ T-cell counts, method of HIV 
infection), diseases, and therapies. Much of the outcome research on patients 
with AIDS has been directed primarily on the documentation of mortality 
rates and the determination of prognostic factors. Numerous papers have 
documented the outcomes of patients hospitalized with AIDS, most especially 
patients with Pneumocystis carinii pneumonia (PCP). In the early years of the 
AIDS epidemic (before 1988), studies consistently reported poor survival rates, 
particularly in patients with respiratory failure necessitating mechanical 
ventilation. Most of these patients had PCP, and reported mortality rates 
ranged from 86% to 100%/5,6,9,68,69 \n 1988, mortality rates were noted to 
drop. One study reported mortality among patients with first episodes of PCP 
to be 58%.8 Since this initial report of improved outcome, three studies have 
reported in-hospital mortality rates (in AIDS patients with pneumonia 
requiring mechanical ventilation) that confirm this lower mortality rate.4'7'16 
Following this trend in improved in-hospital survival in AIDS 
patients with pneumonia (either due to P. carinii or another pathogen), out¬ 
patient survival rates were reported to be improving as well. In 1990, two 
reports documented improved short-term (1-year) out-patient survival rates 
from 1984 through 1987.Hdi By 1991, in a study of AIDS patients who were 
admitted with acute respiratory failure due to PCP between January 1, 1987 
and December 31, 1990, in-hospital mortality was 53% and 1-year mortality 
was 63%.13 
In addition to longitudinally tracking mortality rates, researchers have 
focused their attention on the elucidation of prognostic factors for patients 
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with AIDS. Numerous clinical and laboratory variables have been 
documented to have prognostic value in stratifying AIDS patients. In 1987, 
Brenner et. al.12 linked poor outcomes in patients with PCP to five 
determinants: (1) severe abnormalities on initial chest radiographs, (2) 
alveolar-arterial oxygen gradient (AaPO?) greater than 30 mm. Hg, (3) severity 
of interstitial edema on initial transbronchial biopsy, (4) the persistence of 
Pneumocystis cysts on follow-up biopsy, and (5) diagnosis of PCP before July, 
1985. Brenner et. al. also reported that total leukocyte counts has no 
prognostic significance for either acute or long-term life expectancy. 
In 1988, El-Sadr and Simberkoff8 reported that survival of patients with 
PCP was predicted by a constellation of clinical and laboratory findings: a short 
duration of symptoms (most commonly shortness of breath, cough, fever, 
chest pain, and weight loss), better arterial oxygenation on admission, and a 
decrease in serum lactate dehydrogenase (LDH) and an improvement in 
arterial blood gas determinations after institution of mechanical ventilation. 
In 1991, Peruzzi et. al.70 reported that, in patients with PCP, the presence of 
metabolic acidemia (a pH < 7.35 and a base deficit > 4 mEq/L) and prolonged 
positive end-expiratory pressure (PEEP) > 10 cm. H2O were poor prognostic 
signs. Peruzzi et. al., in disagreement with Brenner et. al., reported that chest 
radiographic findings did not predict mortality in this group of patients. 
Serum LDH was determined to be of prognostic value in patients with 
PCP by several groups of researchers. In 1988, Lipman and Goldstein71 
presented evidence that serum LDH in PCP patients had high prognostic 
value. Serum LDH values greater than 520 IU had a 100% sensitivity of 
predicting death and a specificity of 61%. These results were confirmed by two 
groups of researchers. Kagawa et. al., though primarily studying the use of 
serum LDH in the diagnosis of PCP, concluded that serum LDH "correlates 
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with the severity of [PCP patients'] oxygen transfer disorder."72 Garay and 
Greene determined that serum LDH levels, AaPCb gradients, and mean 
respiratory rates had prognostic value for patients with PCP.77 
Of note, Garay and Greene found no significant difference between PCP 
survivors and nonsurvivors "with respect to duration of symptoms, presence 
of physical findings (other than respiratory rate), and admission leukocyte or 
lymphocyte counts."73 This is in agreement with Brenner's findings 
concerning leukocyte counts and in disagreement with El-Sadr and 
Simberkoff’s results concerning symptom duration. 
Besides the determination of individual prognostic factors for patients 
with AIDS (predominantly with PCP), two separate prognostic scoring 
systems have been developed for patients with AIDS. The AIDS Prognostic 
Staging System,74 created by Justice and Feinstein in 1989, was designed to 
stratify hospitalized and non-hospitalized AIDS patients according to 
predicted long-term mortality. The system, developed and tested on a cohort 
of 117 AIDS patients between October, 1981 and July, 1987, divides patients 
into three stages based on four potential forms of physiologic deficit: 
nutritional, respiratory, neurologic, or hematologic. One point is given for 
each of the following: severe diarrhea or serum albumin < 2.0 g/dl, any 
neurologic deficit, arterial oxygen tension < 50 mm Hg, hematocrit < 30 
percent, lymphocyte count < 150/gl, white blood cell count < 2500, and 
platelet count < 140,000 (Table 3). The total score determines the assignment 
of stage: Stage I (0 points). Stage II (1 point), and Stage III (2 to 7 points). In so 
far as the initial cohort of 117 patients with AIDS, the AIDS Prognosis score 
proved to be a reliable means of stratifying patients according to out-patient 
mortality: patients in Stages I, II, and III had median survival times of 11.6, 
5.1, and 2.1 months, respectively. 
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Table 3: The AIDS Prognosis Score 
Characteristic Points Awarded 
Nutritional 
— Severe diarrhea and/or 
serum albumin < 2.0 g/dl 1 
Respiratory 
-- P02 < 50 mm Hg 1 
Neurologic 
— Any manifestation 1 
Hematologic 
— Lymphocytes < 150 1 
— Hematocrit < 30% 1 
— White blood cells < 2,500 1 
— Platelets < 140,000 1 
The second AIDS-specific prognostic scoring system developed was the 
PCP Severity Score (PSS).75 Created by Speich et. al. in 1990, the PSS was 
developed on a cohort of 59 nonintubated PCP hospitalized patients. It was 
designed to stratify this group of patients according to mortality within 14 
days aftPr bronchoscopy. The score is constructed by the degree of abnormality 
of three measures: alveolar-arterial oxygen gradient (AaPO?), serum LDH, 
and percentage of brochoalveolar lavage (BAL) neutrophils (Table 4). These 
variables were chosen by statistical analysis and is in agreement with many of 
the previously discussed reports. Variables which were found to have no 
statistical significance included duration of symptoms, hemoglobin, total 
leukocyte and lymphocyte counts, and C-reactive protein. It should be noted 
that Speich et. al.'s finding that total leukocyte and lymphocyte counts are 
not prognostically significant are in agreement with the results reported by 
Garay and Greene but are in disagreement with those reported by Justice and 
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Feinstein. However, the disagreement between these results could be a 
function of the different outcomes being measured (14 day mortality versus 
long term mortality). The PSS was validated in 1992 in a prospective 
evaluation of 94 patients with PCP. In this follow-up validation study, the 
PSS displayed an overall diagnostic accuracy of 95.7%. 
Table 4: The PCP Severity Score 
Points AaPCb (mm Hg) LDH (U/l) BAL neutrophils (%) 
1 > 20 > 460 >2 
2 > 30 > 920 >5 
3 > 40 > 1,380 > 10 
4 > 50 > 15 
5 > 60 > 20 
As reviewed above, although AIDS-specific prognostic scoring systems 
have been developed and numerous prognostic factors have been 
determined, there is disagreement concerning the validity of individual 
prognostic factors. Therefore, the utility of these systems and factors is 
limited. 
In contrast to the AIDS-specific scoring systems mentioned above, the 
APACHE II prognostic scoring system has been used extensively and 
independently validated. However, because APACHE II was devised before 
the rapid spread of HIV infection, the accuracy of APACHE II in respect to 
patients with AIDS is open to question. By September 1990 (the date of 
inception of the current study), only one research group had published results 
of applying APACHE II to patients with AIDS. 
Smith et. al. published the results of their research in October 1989.59 
Analyzing data collected retrospectively from the medical records of 83 MICU 
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patients with AIDS admitted between January 1984 and September 1988, they 
found that APACHE II significantly underestimated in-hospital mortality 
(45.8% (E) vs. 63.9% (O)) (Table 5). The inaccuracy of the APACHE II mortality 
prediction was shown to be due solely to an underprediction of mortality in 
patients with Pneumocystis carinii pneumonia (PCP) requiring mechanical 
ventilation. In patients with PCP (n=37), predicted mortality was significantly 
less than observed mortality (44.3% vs. 86.5%), whereas in all other AIDS 
patients without PCP (n=46) predicted and observed death rates were similar 
(47.0% vs. 45.7%). The similarity of predicted and observed mortality rates 
extended to AIDS patients without PCP who required mechanical ventilation 
(n=17) (72.3% vs. 76.5%) and AIDS patients without PCP who did not require 
mechanical ventilation (n=22) (31.6% vs. 36.4%). 
Table 5: Comparison of APACHE II Predicted and Observed Mortality (Smith et. al.) 
Predicted Mortality Observed Mortality 
Group Rate, % Rate, % 
All Non-AIDS (n=166) 34.1 31.3 
Mech vent (n=25) 48.1 52.0 
Total AIDS (n=83) 45.8 63.9 
Mech vent & PCP (n=37) 44.3 86.5 
Not mech vent & PCP (n=46) 47.0 45.7 
Mech vent, non-PCP (n=17) 72.3 76.5 
No mech vent, non-PCP (n=22) 31.6 36.4 
Also, it was reported that mean APACHE II scores did not differentiate 
survivors from nonsurvivors (22.8 vs. 26.0) nor differentiate survivors from 
nonsurvivors in the subset of mechanically ventilated patients with PCP (23.4 
vs. 22.3) (Table 6). However, when the subset of mechanically ventilated 
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survivors from nonsurvivors (22.6 vs. 31.6). 
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Table 6: Comparison of APACHE II Scores Between Survivors and Nonsurvivors (Smith et. al.) 
Group Survivors Nonsurvivors p Value 
All non-AIDS 15.5 ±7.0 27.2 ± 8.6 < 0.01 
All AIDS 22.8 ± 5.7 26.0 ± 9.1 NS 
Mech vent & PCP 23.4 ± 4.0 22.314.7 > 0.05 
All other AIDS 22.6 ± 6.1 31.6 ± 11.3 < 0.01 
Smith et. al. explained that the discrepancy between predicted and 
observed mortality rates in patients with PCP (and, by extension, in the entire 
AIDS population) is most likely due to the lack of a specific APACHE II 
diagnostic category coefficient that accurately reflects the severity of PCP. In 
other words, the failure of APACHE II to successfully stratify patients with 
AIDS was caused by APACHE II's underestimation of the severity of PCP. 
Because the patient population studied by Smith et. al. was composed 
exclusively of Veterans (presumably male and predominantly not 
homosexual), there was some uncertainty as to the validity of the results in 
respect to a more typical urban population. As well, because Smith et. al. 
studied a population admitted to the MICU between January 1984 and 
September 1988 (prior to improved PCP survival rates), it was felt that 
another study of the application of APACHE II to HIV-positive patients 
(including patients admitted after 1988 with the prospect of improved 





The current study involved a review of the medical records of all HIV- 
positive patients admitted to the Yale-New Haven Hospital medical intensive 
care unit (MICU) during a five year period. Records were selected by hospital 
discharge date, between October, 1986 and September, 1991. The patients were 
identified by a computerized search of patient records by the ICD-9 
(International Center for Disease, ninth edition) coding of their diagnoses. 
Patients were included by being identified as having either AIDS, AIDS- 
related complex (ARC), HIV seropositivity, or any of the AIDS-associated 
opportunistic diseases (Pneumocystis carinii pneumonia, Kaposi's sarcoma, 
progressive multifocal leukoencephalopathy, or central nervous system 
lymphoma, etc.). A list of 181 admissions was compiled. Eleven admission 
records were either incomplete, could not be located by the medical records 
department, or were otherwise unavailable for review. Of the remaining 170 
records, eight were excluded because the patients had AIDS-associated diseases 
though were not HIV positive and did not have AIDS or ARC. (The patients 
were immunosuppressed for another reason, ie. post transplant, malignancy, 
chronic high-dose steroid use). One record was excluded because the patient 
was infected with HIV type II, not the usual HIV type I. One record was 
excluded because the patient was found never to have been admitted to an 
ICU, and two records were excluded because the patients had been admitted to 
the surgical ICU, not the medical ICU. Among the 158 records remaining, it 
was discovered that some patients had multiple admissions to the MICU 
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which were not identified by the initial computer search. These MICU 
admissions were counted as separate if they occurred during different hospital 
admissions, occurred during the same hospital admission but at least four 
days apart, or if the patients were admitted to the MICU for different reasons 
(if the patients were placed in different diagnostic categories according to 
APACHE II admission criteria). Three records fell into this last category of 
being absent from the computer-generated list. Thus, in total, 161 admission 
records were utilized. 
Data Collection 
Medical records were reviewed retrospectively between December, 1991 
and June, 1992 with the approval of the Human Investigation Committee. 
APACHE II data were obtained from multiple information sources in the 
patients' charts including MICU admission notes, progress notes, transfer 
notes, MICU nursing admission sheets, emergency room admission sheets, 
emergency room transfer sheets, paramedic or ambulance transfer sheets, and 
laboratory reports. In addition to information required for APACHE II 
scoring, information of potential or reported prognostic value was recorded. 
This included HIV risk factor, HIV diagnosis date, leukocyte counts and 
differentials, CD4+ counts, orders regarding maximal supportive and 
resuscitative care ("Do not resuscitate" and/or "Do not intubate" orders), 
identification of microbial pathogens, serum lactate dehydrogenase levels, 
number of procedural interventions, location of treatment prior to admission 
to the MICU, and chest radiographic findings. 
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All information necessary for APACHE II scoring was collected as 
prescribed by Knaus et. al. except that we recorded the most abnormal value of 
any physiologic variable beginning two hours prior to MICU admission and 
ending 22 hours after MICU admission. This small change was instituted in 
order to account for the previously reported problem of lead-time bias76 
resulting from intensive care level services (intubation, administration of 
intravenous cardiac inotropes, etc.) being delivered before the patient was 
physically within the MICU (in other words, while in the ambulance, in the 
emergency room, or on the floor). The only time that this did not apply was 
if the pafient died within the first 22 hours within the MICU. In this case, the 
earliest (though not prior to the decision to admit the patient to the MICU) 
recorded variables (not the most abnormal), were used for the calculation of 
the APACHE II acute physiology score. (Otherwise, heart rate, blood pressure, 
respiration rate, and Glascow coma scale would need to be recorded as zero, 
thus overestimating severity of illness.) Based on past reports,77'7^ and in the 
method of Knaus et. al.,79 if any acute physiologic variable recordings were 
not available, it was assumed that the variable fell with in the normal range. 
Although APACHE II was developed as a prospective scoring system, 
our time constraints made retrospective chart review more feasible for our 
study. Thus, our data collection differed from the manner used by Knaus et 
al. during the validation study for APACHE II. However, in order to 
maintain agreement with the validation study, we only recorded data which 
was prospectively available. This was done by relying on information 
provided by the patient's bedside clinicians as the primary data for diagnostic 
category assignment. However, in event that the patient's physician did not 
clearly indicate a primary diagnosis, we would assign a diagnostic category 
based on prospectively available information (information which was 
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available two hours prior to or within the first twenty-two hours of MICU 
admission) and assisted by decisionmaking algorithms. 
The circumstance in which clinicians did not specify a primary 
diagnosis was not unusual. Typical of these cases were patients being 
admitted with such diagnoses as "hypotension, fever, short of breath", or 
"questionable pneumonia, rule out sepsis," or "dyspnea, fever, rule out 
congestive heart failure versus pneumonia," or "abdominal pain, fever, 
questionable sepsis versus gastrointestinal perforation." For these situations, 
prospectively available (available to the original clinician) clinical 
information such as previous sputum and blood culture results, concurrent 
Swan-Ganz catheter readings, and the presence or absence of free air on an 
upright abdominal X-ray was used. This is not to say that the actual bedside 
clinician's prospective clinical judgment was ever ignored. We assigned 
diagnostic categories only if the initial clinical assignment of diagnosis was 
unclear or ambivalent. 
In instances of similar and frequent clinical situations, in order to 
facilitate the consistent assignment of diagnostic categories, guidelines were 
established (as suggested by Knaus et. al.)80 so as to eliminate variation in our 
retrospective decisionmaking process. This was done to clarify three clinical 
scenarios. One involved the assignment of a diagnostic category to seizure 
patients being admitted to the MICU. If the patient was intubated and 
mechanically ventilated in the MICU (in the setting of a prior or ongoing 
seizure), the patient was categorized as a post respiratory arrest patient. If the 
patient was not intubated due to the prior seizure, though still transported to 
the MICU for observation and monitoring of his or her neurologic and 
respiratory status, then the patient was categorized as a seizure patient. 
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A second situation in which decisionmaking criteria were established 
involved the distinction between the diagnostic categories of "respiratory 
infection" and "sepsis." (In this study, every patient who had a "respiratory 
infection" had pneumonia. Thus, for the remainder of this report, this 
diagnostic category will be referred to as "pneumonia.") In this situation, as 
usual, the patients' prospective clinical diagnosis was considered first and 
foremost. If a question still remained as to the correct diagnostic 
categorization, prospectively-available lab results were next considered, and 
in instances of continuing uncertainty, systolic blood pressure (SBP) and 
alveolar-arterial oxygenation gradient (AaPCb) was examined. In general, 
previously positive blood cultures, a low SBP (< 90 mm. Hg.), and low AaPCb 
were factors increasing the probability that the patient would be categorized as 
septic. Conversely, negative blood cultures, a SBP > 90, and a high AaPCb led 
more frequently to a disease categorization of pneumonia. 
A third situation in which a guideline was established in order to 
reduce inconsistency involved patients who had had emergency life support 
measures taken in their behalf (patients who had been "coded"). When faced 
with the decision of whether to classify a patient who had a respiratory arrest 
which then progressed to a cardiac arrest, it was decided that any patient who 
received intravenous cardiac inotropes, chronotropes, or mechanical 
stimulation (chest compressions) would be categorized as a post cardiac arrest 
patient. If the patient had a respiratory arrest (was subsequently intubated and 
ventilated) yet did not require nor receive cardiac inotropes he or she would 
be categorized as a respiratory arrest patient. 
In order to consistently evaluate and determine the chronic health 
status of individual patients, we established a guideline for immunologic 
status assessment. This was done because it was felt that not all HIV-positive 
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patients admitted to the MICU were significantly immunocompromised nor 
would their HIV seropositivity greatly effect their survival from their acute 
illness and hospitalization. Examples of this situation are numerous: a 
recently diagnosed and asymptomatic HIV-positive patient admitted to the 
MICU because of a non-immunologically related illness, such as an asthmatic 
crisis, a self-administered drug overdose, or trauma. The guidelines are as 
follows: The patient was felt to be immunologically compromised (and given 
points for a chronic disease history) if (1) he/she were HIV-positive and had a 
history of Pneumocystis carinii pneumonia (PCP), Kaposi's sarcoma (KS), 
cytomegalovirus (CMV) retinits, cryptococcal meningitis, or any other AIDS- 
defining disease, (2) he/she were HIV-positive for 24 months or longer, (3) 
he/she were diagnosed as HIV-positive at least one month prior to hospital 
admission, and he/she were admitted to the hospital or MICU due to 
infection, lymphoma, cachexia, or an immunologically mediated illness. 
Conversely, if the patient were diagnosed as HIV-positive for less than 24 
months, without a history of an AIDS-defining illness, and were admitted to 
the hospital with a non-immunologically mediated illness, then he/she was 
felt to be non-immunocompromised and therefore did not receive any 
chronic health points (unless for other organ system failure). Using this 
"immunosuppression guideline", 151 patients were given "chronic health 
points" for having either a history of severe organ system insufficiency or 
immunosuppression prior to hospital admission. 
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Data Analysis and Statistical Methods 
Medical record information was collected on data entry sheets and 
transferred into a data management information system (Reflex® and 
Quatrop^o® software). This software was capable of performing all needed 
data retrieval and sorting functions. Data are expressed anci analyzed so as to 
facilitate easy comparison with previously published APACHE II data. In 
general, means are expressed ± the standard deviation (SD). Predicted 
mortality risk was calculated using the APACHE II multiple logistic 
regression equation. The significance of differences among groups of 
continuous variables was determined by the unpaired Student's t-test and by 
Chi-square tests or binomial distributions for groups of dichotomous 
variables. Statistical significance is defined as p <0.05, unadjusted for 
multiple comparisons. 
ILL RESULTS 
The patient population, represented by the 161 patient records (which 
for the matter of discussing patient demographics will be considered to 
represent 161 patients) consisted of 43 women and 118 men. The mean age of 
the population was 37 years old (S.D.= 8.7), with a range from 21 to 79 years 
old. The racial mix of the group was 92 Blacks, 14 Hispanics, 54 Whites, and 1 
Native American (Table 7). The vast majority (97%) of the patients were 
nonsurgical admissions. Most patients were transferred to the MICU from 
either the emergency room or from another hospital floor (Figure 4). During 
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the five years of this study, the number of HIV-positive patients who were 
admitted to the MICU fluctuated without a clear relationship to the total 
number of HIV-positive patients who were admitted to the hospital. 
The population's HIV risk factors were summarized. Of the total 161 
patients, 107 patients (66%) had a history of intravenous drug use (IVDA), 34 
patients (21%) had a history of homosexual activity, 9 patients (6%) had a 
history of both IVDA and homosexual activity, and 29 patients (18%) denied 
both HIV risk factors (Table 7). Of the 29 patients without either risk factor, 
many had become HIV infected by known sources or by known risks: as a 
recipient of infected blood, or through sexual contact with a high risk partner 
(ie., a known IV drug user, a known HIV-positive partner, or a prostitute). 
It was observed that the risk factors associated with HIV infection 
varied according to patients' sex and race. A history of IVDA was greatest in 
black males (84%), hispanic males (82%), and white women (90%). 
Homosexual activity, known not to be an HIV risk factor for women, was, as 
expected, confined to the male population. Within the male population, 
homosexual activity accounted for a larger degree of HIV transmission in the 
whites than in other races (White: 45%, Black: 19%, Hispanic: 18%) (Table 7). 
IVDA was an equal factor leading to HIV infection among both females and 
males (72% vs. 71%). 
The classification of the population according to disease category 
showed a predominance of MICU admissions due to infection (78 patients, 
48%), either in the form of pneumonia (44 patients, 27% of the total 
population), septic shock (29 patients, 18%), or a neurologic infection (5 
patients, 3%) (Figure 5). Other not uncommon diagnoses were 
gastrointestinal bleeding (15 patients), cardiac arrest (9 patients), self¬ 
intoxication (7 patients), respiratory arrest (6 patients), seizure (5 patients) and 
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electrolyte/acid-base disturbance (5 patients). The remaining 50 patients were 
assigned one of the other thirty diagnostic categories. Changes in disease 
presentation over time were not statistically significant (data not shown). 
Regarding initial severity of illness, the population's mean APACHE II 
score was 20.0 (S.D. = 8.63), the median was 19, the range was from 1 to 45, and 
the distribution of scores reached its zenith between 15 and 19 (Figure 6). The 
population's severity of illness (as reflected by APACHE II scores) over the 
five year period of study did not show statistically significant changes (data 
not shown). 
Regarding APACHE II's prognostic capability, APACHE II had a correct 
outcome classification rate (with a mortality prognosis > .50 implying 
predicted death) of 67.1%. This correct classification rate was not markedly 
improved using a wide range of cutoff points (Table 8). A receiver operator 
characteristics (ROC) curve was constructed based on sensitivity and 
specificity values. (Figure 7). 
When the APACHE II prognostic scoring system was applied to the 
entire cohort population, APACHE II significantly underestimated the in- 
hospital mortality rate (35.5% estimated (E) vs. 44.1% observed (O), p < .025). 
However, this discrepancy was largely explained by the fact that APACHE II 
underestimated mortality in patients with pneumonia (n=44) (28.5% (E) vs. 
50.0% (O), p < .005) (Table 9 and Figure 8). In patients without pneumonia 
(n=117), APACHE II correctly estimated mortality (38.1% (E) vs. 41.9% (O)). In 
the second largest disease category, sepsis (n=29), APACHE II slightly 
overestimated mortality in patients with sepsis though this was not 
statistically significant (56.4% (E) vs. 41.3% (O)). 
Because Smith et. al. reported that APACHE II underestimated 
mortality in patients with Pneumocystis cnrinii pneumonia (PCP),59 we 
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investigated whether APACHE II underestimated mortality in patients with 
pneumonia of any etiology or only due to P. cnrinii. In our 44 patients with 
pneumonia, the most common organism isolated was Pneumocystis cnrinii:: 
19 patients (43%) were identified to have been solely infected with P. cnrinii 
and 7 patients had polymicrobial infections with P. cnrinii (Figure 9). In the 
other 18 patients with pneumonia, 11 patients had other pathogens identified, 
and 7 patients never had a pathogen identified. Common pathogens, beside 
P. cnrinii, were Staphylococcus nureus, Streptococcus pneumonine, 
cytomegnlovirus (CMV), and Hnemophilus influenzn. 
The manner in which the respiratory pathogen was identified in our 
population was variable, but often the definitive diagnosis was made by 
invasive means (bronchoaveolar lavage, direct lung biopsy, or tissue sample 
at autopsy). Of the 44 patients with pneumonia, 27 of them (61%) had a 
negative initial sputum culture and/or stain (Table 10 A). Of the 27 patients 
with negative sputum cultures/stains, 20 later had positive microbial 
identification by one of the more invasive studies. Consequently, the 
sensitivity of sputum culture and stain in our study population was 46% (17 
of 37) and the negative predictive value of 26% (7 of 27). Much of the lack of 
sensitivity is due to lack of sensitivity concerning P. cnrinii detection. Of the 
26 patients with documented P. carinii infection, only 6 had P. cnrinii 
identified from their sputum (17 were identified by BAL, and 3 were 
identified by tissue sample, either at autopsy or direct lung biopsy). Thus, the 
sensitivity of initial sputum stain and culture in identifying P. cnrinii was 
only 23.1% (Table 10 B). 
Because infection with P. carinii was the most prevalent cause of 
pneumonia in the study population, estimated and observed mortality rates 
in pneumonia patients with and without P. cnrinii infection were compared. 
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APACHE II accurately predicted mortality in patients with PCP (28.2% (E) vs. 
34.6% (O)) but significantly underestimated mortality in patients with 
pneumonia of another etiology (28.9% (E) vs. 72.2% (O), p < .005) (Table 11 A). 
Because of concern that these results were influenced by the uncertainty that 
was introduced by seven patients never having a pathogen identified, we 
reanalyzed the results separating these seven patients (Table 11 B). This 
reanalysis yielded results which suggested that APACHE II underpredicted 
mortality in both groups of patients whose pneumonia was not caused by P. 
carinii (those with another pathogen identified and those who never had a 
pathogen identified). 
Initial data analysis demonstrated that APACHE II's capacity to predict 
group mortality rates was correlated with patients' initial severity of illness 
(measured by APACHE II scores). It appeared as if APACHE II accurately 
predicted group mortality rates in patients with high APACHE II scores (>25), 
was less accurate in patients with high mid-range APACHE II scores (20-24), 
was inaccurate in patients with low mid-range APACHE II scores (15-19), and 
was most inaccurate in patients with low APACHE II scores (<14) (Table 12 
and Figure 10). However, after patients with pneumonia were excluded, it 
was observed that the initial inaccuracy in the distribution of the lower 
APACHE II scores (<14 and 15-19) disappeared (Table 13, Figure 11). However, 
in patients with pneumonia, the distribution of APACHE II scores was 
important. APACHE II accurately predicted mortality in pneumonia patients 
with APACHE II scores > 14. In pneumonia patients with APACHE II scores < 
14, predicted mortality was significantly less than observed mortality (Table 
14, Figure 12). 
Similar to the inaccuracy of APACHE II in predicting mortality in 
patients with pneumonia, mean APACHE II scores proved unable to 
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differentiate between survivors (S) and nonsurvivors (NS) with pneumonia 
(18.9 (S) vs. 21.5 (NS)) (Table 15). In all other patients, survivors' mean 
APACHE II score was significantly lower than the mean score in 
nonsurvivors (17.3 (S) vs. 26.3 (NS), p < .005 ). 
During the evaluation of outcomes, unanticipated differences in 
survival were observed in patients with pneumonia. Patients with PCP had a 
significantly greater survival rate than patients with pneumonia of another 
etiology (65.4% vs. 27.8%, respectively, p < .014) (Table 16 A). This difference 
existed despite the two groups' similar initial prognoses (as measured by 
APACHE II scores) and their need for respiratory support (intubation and 
mechanical ventilation) (Table 17). The difference in survival rates was 
basically unchanged if only intubated patients were considered (63.6% in 
intubated patients with PCP vs. 26.7% in intubated patients with pneumonia 
of another etiology) (data not shown). 
When pneumonia patients who never had an organism identified 
were separated into their own group, a difference in survival rates remained: 
14.3% survival of patients with pneumonia without microbial identification, 
36.4% survival of patients with non-P. carinii pneumonia, and 65.4% 
survival of patients with PCP. The difference in mortality rates was 
statistically significant between patients with PCP and patients with 
pneumonia of unknown etiology. The difference in mortality between 
patients with PCP and patients with pneumonia caused by another known 
pathogen was not statistically significant (though perhaps still clinically 
significant) (Table 16 B and 16 C). 
The degree of immunosuppression was investigated to determine its 
relationship to medical outcomes. Initially CD4+ T-cell count were recorded. 
However, since only 34 of 161 patients' charts contained these values, we 
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decided to use the total lymphocyte count (TLC) as our marker of 
immunosuppression. This was in accordance with a report that TLC is an 
accurate measure of CD4+ counts.81 TLC was calculated for each patient using 
the following formula: TLC = # of White blood cells (WBC's) x % of WBC's 
which were lymphocytes (lymphocyte differential). In the total cohort of 148 
patients with adequate information, a TLC < 200 was significantly associated 
with increased mortality (p = .003) (Table 18 A). Because it was postulated that 
TLC would be most significantly associated with mortality rates in patients 
with infection, we reanalyzed the data separating patients with either 
pneumonia or sepsis. A TLC < 200 was found to be significantly associated 
with increased mortality in patients with infection (p = .003) but not 
significantly associated with outcome in all other patients (without 
pneumonia or sepsis) (p = .105) (Table 18 B and 18 C). When the patients with 
infection were separated into their original diagnostic categories (pneumonia 
or sepsis), it was observed that TLC < 200 was significantly associated with 
mortality in pneumonia patients. In patients with sepsis, although TLC < 200 
was positively correlated with increasing mortality, it was not statistically 
significant (Table 18 D and 18 E). 
In addition to assessing the effect of TLC on survival, we studied 
APACHE IBs predictive accuracy in relation to the location of treatment prior 
to admission or transfer to the MICU. Estimated and observed mortality were 
analyzed for patients in the two largest patient groups: those patients 
admitted from the emergency room (n=81) and those transferred from other 
hospital floors (n=72). APACHE II accurately estimated mortality in patients 
admitted from the emergency room (37.6% (E) vs. 44.4% (O)), but significantly 
underestimated mortality in patients transferred from other hospital floors 
(33.3% (E) vs. 44.4% (O), p < .05) (Table 19). 
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Because AIDS has focused so much attention on ICU utilization and 
cost issues, APACHE II's accuracy relationship to patients' length of stay (LOS) 
in the MICU was evaluated. The cohort had a mean MICU LOS of 7.3 ± 15.0 
days (± SD). In respect to mortality, it was found that APACHE II correctly 
estimated mortality in the 144 patients with a MICU LOS < 14 days (34.9% (E) 
vs. 40.3% (O)) but underestimated mortality in the 17 patients with a MICU 
LOS > 14 days (41.0% (E) vs. 82.4% (O), p < .005) (Table 20). 
IV. DISCUSSION 
This study was undertaken in order to evaluate the APACHE II 
prognostic scoring system when applied to an HIV-positive population 
admitted to the MICU. It was observed that APACHE II significantly 
underestimated mortality in the HIV-positive population to which it was 
applied. This discrepancy, however, was due to a selective underestimation 
of mortality among patients with pneumonia. In patients without 
pneumonia, APACHE II accurately predicted mortality. Interestingly, 
although APACHE II underestimated mortality in patients with respiratory 
infection (pneumonia), it correctly predicted (in fact, slightly overestimated) 
mortality in patients with systemic infection (sepsis). 
The results of this study both agree with and conflict with results 
previously reported by Smith et. al.. Both studies found that APACHE II 
significantly underestimated mortality in HIV-positive patients. As well, 
both studies found that mean APACHE II scores were significantly different 
between survivors and nonsurvivors in patients not diagnosed with 

47 
pneumonia. However, our results differ from those reported by Smith et. al. 
in the explanation given for APACHE IPs shortcomings. Whereas Smith et. 
al. reported that APACHE IPs inaccuracy is caused by underestimating 
mortality in patients with PCP,59 our results indicate that APACHE IPs 
inaccuracy in HIV-positive patients is due to an underestimation of mortality 
in patients with pneumonia, particularly in patients with non-Pneumocystis 
carinii pneumonia (NPCP). In this study, APACHE II correctly predicted 
mortality among patients with PCP. 
This conflict between our results and those of Smith et. al. may be 
related to the difference in observed PCP mortality rates between the two 
studies. Smith et. al. studied a population of PCP patients with a mortality 
rate of 86.5% while the current study's PCP patients had a mortality rate of 
only 34.6%. 
The lower mortality rate of our study is likely related to three factors. 
First, the PCP patients in this study were not as acutely ill as the patients 
studied by Smith et. al. (as determined by differences in predicted mortality 
rates, 28.2% vs. 45.8%, respectively). This may be due to differences in 
protocol between Yale-New Haven Hospital (YNHH) (the hospital in this 
study) and the New York Veterans Administration Medical Center 
(NYVAMC) (the hospital in the study by Smith et. al.). For instance, the 
threshold of illness which engendered a patient to be transferred to the MICU 
may have been much lower at YNHH than at the NYVAMC. Therefore, the 
patients included in this study would be less severely ill than those patients 
included in the study by Smith et. al. 
Second, because the patients in this study were admitted to the MICU 
later in the "AIDS epidemic," (October 1986 to September 1991), they could be 
expected to have lower mortality rates based solely on the trend toward better 
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outcomes in PCP patients. Whether the decreased mortality rates are due to 
better treatments for both P. carinii infection and HIV infection (ie., 
pentamidine and AZT) or to a decreased virulence of P. carinii is not known. 
And third, a selection bias probably exists. Because data was 
retrospectively collected in both studies, the assignment of diagnostic 
categories was based on the judgment of the patients' bedside clinicians. 
However, in this study and presumably in the study by Smith et. al., clinicians 
often would not clearly site a specific diagnosis. In this study, diagnoses of 
"pneumonia, rule out sepsis" were not uncommon in the admitting orders to 
the MICU. Thus, the data collector was forced to make a decision based on the 
available information. However, in such decisionmaking circumstances as 
this, APACHE II does not provide data collectors with detailed guidelines 
concerning the classification of disease. Hence, the assignment of diagnostic 
categories was influenced by the judgment of the data collector. 
Consequently, it is possible that the assignment of patients into the 
disease categories of "pneumonia" and "sepsis" was done differently during 
the two studies. In this study, out of 161 patients, 44 were classified as 
"pneumonia" and 29 were classified as "sepsis." In the study by Smith et. ah, 
out of 83 patients, 54 were classified as "pneumonia" and only 6 were 
classified as "sepsis." Thus, in this study, the ratio of patients with 
pneumonia to those with sepsis was 1.5 whereas in the study by Smith et. al. 
the ratio was 9.0. This difference (1.5 vs. 9.0) in the ratio of patients with 
pneumonia to those with sepsis may reflect an actual difference in the MICU 
populations at the different institutions. However, it seems more likely (as 
will be discussed below) that this difference is due to the manner in which 
patients were assigned to diagnostic categories. Therefore, the observed low 
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rate of mortality in PCP patients in this study may be partially due to the 
presence of selection bias. 
Although the disagreement between this study's results and those of 
Smith et. al. may partially be explained by the difference in PCP mortality 
rates observed during the two studies, the difference in mortality rates 
between the two studies does not explain why APACHE II underestimated 
mortality in all patients with pneumonia in this study. The possible 
explanation for the underestimation of mortality in pneumonia patients is 
threefold. First, as discussed in relation to PCP mortality rates, there is likely 
to be a selection bias affecting all patients with pneumonia. Because the 
APACHE II prognostic scoring system does not provide decisionmaking 
algorithms concerning the assignment of diagnostic categories, individual 
data collectors must make these decisions on their own. This decision enters 
into the calculation of predicted mortality using the APACHE II multiple 
logistic regression equation (See below). Thus, the absence of decisionmaking 
algorithms for the categorization of disease directly influences the predicted 
mortality rate and the prognostic accuracy of the APACHE II system. 
APACHE II multiple logistic regression equation 
In (R/l-R)= -3.517+ .146 (APACHE II score)+ DCW + .603 {only if 
emergency postoperative}, 
R=Risk of death and DCW= Diagnostic category weight 
The lack of algorithms is especially significant for patients whose 
APACHE II scores fall in the middle range of scores. When the APACHE II 
score is either low or high, the relative importance of diagnostic categories is 

50 
small. Within the middle range of scores, however, variations in disease 
classification greatly affect calculated risk predictions. (This is a direct 
consequence of the logistic structure of the regression equation and has been 
confirmed by Knaus et. al. regarding APACHE III.45) 
The conclusion that the APACHE II predicted morality calculations are 
subject to interobserver variation in the assignment of diagnostic categories 
has been previously reported. Jackson et. al. found a large degree of inter¬ 
observer variation in the assignment of diagnostic categories for a small test 
population.83 In the assessment of disease, the four participants in the study 
agreed on the disease categorization in only four of the ten patients. Concern 
about interobserver reliability (and intraobserver reliability) in the 
determination of precipitating factors of ICU admission has also been 
expressed by Teres and Lemeshow 42'84 
To further complicate the issue of categorizing a patient with 
pneumonia versus one with sepsis is the lack of consensus regarding the 
definition of sepsis. Working definitions of the terms "bacteremia," 
"septicemia," "sepsis," "sepsis syndrome," and "septic shock" have been 
offered,85 but it is unlikely that they are clinically differentiated in the same 
manner at separate institutions. Consequently, individual clinicians and data 
collectors involved in one study are not likely to be categorizing patients' 
diseases in the same way as individuals involved in a similar study at 
another institution. 
Thus, APACHE IPs inaccuracy in predicting outcome in pneumonia 
patients is likely to be partially due to an absence of precisely defined 
decisionmaking algorithms, and the resulting interobserver variation 
affecting disease categorization. A second potential cause of APACHE II's 
underestimation of mortality in pneumonia patients is an inadequate 
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adjustment for the severity of immunologic suppression by HIV. In the 
comparison of estimated and observed mortality rates in pneumonia patients 
(Table 14, Figure 12), it is apparent that APACHE II's greatest degree of 
inaccuracy focuses on patients with relatively low APACHE II scores and a 
lesser apparent severity of acute illness. However, it is also clear that 
APACHE II slightly underestimates mortality across the entire distribution of 
APACHE II scores. Unlike the results of Smith et. al., which led to the 
conclusion that APACHE II does not adequately adjust for the severity of PCP, 
our results point to a broader deficit: an inadequate adjustment for the effects 
of immunosuppression, particularly in patients with pneumonia with low 
APACHE II scores. 
The third factor which can potentially explain some of the discrepancy 
between estimated and observed mortality in pneumonia patients is the 
significant number of patients with an unknown etiology of their 
pneumonia. It was observed that APACHE II significantly underestimated 
mortality for these patients. This inaccuracy is likely to be the result of two 
things: first, patients with pneumonia of unknown etiology are more likely 
to be infected with CMV or cryptococcus because these organisms are more 
difficult to identify or culture. These patients are also known to be more 
severely immunosuppressed than patients with PCP. Second, the empiric 
antibiotic therapy directed at an unknown organism is likely to be less 
efficacious than specific therapy directed at a known pathogenic agent. The 
combination of these factors helps to explain the low survival rate of patients 
with pneumonia of unknown etiology and the underestimation of mortality 
for pneumonia patients as a whole. 
Thus, APACHE II's underestimation of mortality in patients with 
pneumonia is multifactorial. It is likely due to (1) APACHE II's lack of 
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decisionmaking algorithms; (2) APACHE II's inadequate risk adjustment for 
HIV infection in patients with a diagnosis indicating an infectious etiology; 
and (3) a significant proportion of pneumonia patients in this study 
population without a known etiologic agent for the cause of their 
pneumonia. 
After research on the current study was begun, three more reports 
concerning APACHE II's application to patients with AIDS were published. 
In 1991, Benson et. al.60 published a report which analyzed retrospectively 
collected data from 72 hospitalized patients (not necessarily in the ICU) with 
first-episode PCP admitted between April 1985 and December 1987. Only 12 
patients required mechanical ventilation and the mortality attributable to PCP 
in the total cohort was low (8 deaths). Four parameters (admission serum 
albumin, serum LDH, alveolar-arterial oxygen gradient (AaP02), and the 
APACHE II score) were compared for their ability to predict mortality. Serum 
albumin levels, LDH levels, and APACHE II scores were significantly 
different between the group of survivors and the group of nonsurvivors. In a 
stepwise discriminant analysis, only APACHE II score and serum LDH levels 
were statistically associated with mortality. 
Benson's conclusion, namely that the APACHE II score is one of the 
measures which was significantly associated with mortality in patients with 
PCP, is in frank disagreement with the results previously reported by Smith 
et. al. but is in agreement with the present study's conclusions. This is likely 
a function of either one or both of the following: the improved survival of 
patients with PCP during the latter 1980’s, and the initial severity of acute 
illness (as described by the predicted mortality rates and the need for 
mechanical ventilation) (Table 21). 
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Table 21: Characteristics of Patients with PCI’ in the Different Studies 
which have Applied APACHE II to AIDS 
Author 
Time frame 





Smith 1/84 - 9/88 76% (41 /54) 44.3* 86.5* 
Benson 1/85-12/87 16% (12/75) 14.4** 16.0 
Current study 10/86-9/91 85% (22/26) 28.2 34.6 
This value is based only on those 37 patients who had PCP requiring mechanical ventilation. 
Predicted and observed mortality rates for patients with other types of pneumonia were not 
reported. 
** This value was calculated from the reported mean APACHE 11 scores. 
MV= mechanical ventilation 
Another study concerning APACHE II's application to patients with 
AIDS was presented in the literature in the form of an abstract.61 jiva et. al. 
studied 76 AIDS patients with successive hospital admissions. In 1991, they 
reported that there was a positive correlation between APACHE II scores and 
mortality in AIDS patients. However, it was noted that observed mortality 
was higher at every APACHE II score for patients with AIDS than that 
reported for patients without AIDS. Thus, the APACHE II prognostic scoring 
system, though correlated with mortality outcome, underpredicted mortality 
in patients with AIDS. Unfortunately for the sake of comparison with the 
current study, the percentage of the study population that was categorized as 
having pneumonia was not reported. 
The final study, published in 1992 by Montaner et. al.,62 compared the 
association of the APACHE II score, the acute lung injury (ALI) score, the 
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AIDS Prognosis score, the modified multi-system organ failure (MSOF) score, 
and serum LDH with mortality in patients with PCP. The patient population 
was comprised of 52 ICU admissions between January 1985 and April 1991. 47 
patients (90%) required mechanical ventilation, and the mortality of this 
group was 72%. In the 5 patients who did not receive mechanical ventilation, 
4 died (80%). The results of the study indicate that the MSOF score was the 
only independent predictor of mortality, though there was a positive 
correlation between mortality and both MSOF score and serum LDH. The 
AIDS Prognostic Staging System, the ALI score, and the APACHE II prognostic 
scoring system were found to be poor prognostic tools in this group of 
patients with AIDS. Montaner et. al. conclude that "it is not the severity of 
lung injury that predicts mortality [in patients with PCP], but rather the extent 
of multisystem organ failure." It is unclear whether this conclusion has 
validity in other patient groups. It appears that Montaner et. al. believe that 
survival among critically ill patients is dependent not only upon the severity 
of physiologic abnormality caused by dysfunction in a primary organ system, 
but also upon the degree of other organ system compromise or impairment. 
Although Montaner's results concerning the prognostic accuracy of 
APACHE II when applied to patients with PCP conflict with the present 
study's results, Montaner's conclusion appears to make good clinical sense in 
that patients with mulitsystem organ failure may be expected to have a high 
mortality rate.86 Because the APACHE II prognostic scoring system was 
designed to account for only one factor precipitating admission to the ICU, it 
is systematically unable to accurately adjust for mortality risk in patients with 
multisystem organ failure. It can be argued that all AIDS patients with 
pneumonia requiring mechanical ventilation and/or intensive care 
monitoring have at least two organ systems in failure: respiratory and 
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immunologic. However, APACHE II is only designed to account for 
pneumonia as a factor necessitating ICU admission whereas it accounts for 
immunologic insufficiency in Chronic Health Status. Concern for the 
accuracy of APACHE II in patients with multisystem organ failure is 
especially relevant in AIDS patients because of the complexity of disease 
manifest by AIDS patients. Consequently, patients with AIDS may have 
outcomes (survival versus nonsurvival) that are not primarily caused by the 
initial disease process which precipitated MICU admission. 
The observation that multisystem organ failure presents difficulties to 
the APACHE II system was acknowledged by Knaus and his colleagues when 
they stated that "[i]t may be difficult in patients with multi-system failure to 
decide which system failure is primary and which is secondary, etc. Your best 
clinical judgment is to be used to make the decision; and if two systems are 
assessed to be 'equal' in failure, one system can be 'arbitrarily' indicated as 
primary."80 
Thus, Montaner’s results imply that in patients with pneumonia and 
known severe immunosuppression, APACHE II is inaccurate because it does 
not adequately account for multisystem organ failure and, thus, should be 
expected to underestimate mortality rate. This conclusion is somewhat 
supported by our findings that TLC < 200 is strongly associated with 
increasing mortality in patients with pneumonia. In addition, this finding 
may help explain why, in this study, APACHE II so greatly underestimated 
mortality in patients with pneumonia and low APACHE II scores. Perhaps 
the group of pneumonia patients with low APACHE II scores who did not 
survive hospitalization were actually more severely immunocompromised 
(TLC < 200) than those who survived. Although the cause of this discrepancy 

is uncertain, the degree of "unaccounted" immunosuppression may be of 
explicative value. 
Our results indicate that APACHE II's accuracy in predicting mortality 
rates varies according to the treatment location prior to admission to the 
MICU. APACHE II accurately estimated mortality in patients admitted from 
the emergency room, but significantly underestimated mortality in patients 
transferred from other hospital floors. This confirms the results previously 
reported by Escarce.66 
In respect ICU utilization, our results indicate that the accuracy of 
APACHE II's estimated mortality rates was dependent on the length of stay 
(LOS) of patients in the MICU. APACHE II correctly estimated mortality in 
patients with a MICU LOS < 14 days but underestimated mortality in patients 
with a MICU LOS > 14 days. This difference between mortality rates according 
to length of stay in the MICU supports the finding of a similar difference 
recently reported concerning very old patients (>80 years) who were being 
mechanically ventilated in the MICU.82 
Although the APACHE II system has received its share of criticism, 
many of the weaknesses of APACHE II have been acknowledged by Knaus et. 
ah, and aPACHE II was subsequently modified to incorporate some necessary 
changes. The result of these changes was the APACHE III prognostic scoring 
system which was validated on a cohort of 17,440 patients.45 The APACHE III 
prognostic scoring system, as expected, is based on the same conceptual 
approach as the original APACHE system and APACHE II. However, changes 
were made in selecting and weighting the physiologic variables which 
determine the acute physiology score (more variables were chosen, and the 
weights have a greater range). The concern for lead-time bias in terms of 
location and duration of treatment prior to ICU admission has been 
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addressed. The number of diagnostic categories was expanded from fifty-three 
to seventy-eight, allowing for more precision in the categorization of disease, 
and the diagnostic category weights were revised. As well, the determination 
of physiologic reserve was reworked. The age assessment has been re¬ 
weighted and the list of significant comorbid conditions has been 
substantially redefined (only those comorbid conditions which influenced 
patients' immunologic status were found to be significant upon statistical 
analysis). 
At present, the published results of APACHE III indicate that its overall 
explanatory power is greater than that of APACHE II. However, in relation to 
our study, its accuracy when applied to an HIV-positive population and 
specificcdly to HIV-positive patients with non-Pneumocystis carinii 
pneumonia has not been independently validated. This is one area which 
warrants future research, particularly in relation to patients with pneumonia 
(either PCP or NPCP). As well, our results indicate that some measure of the 
severity of immunosuppression (if available, CD4+ T-cell counts; if not 
available, then total lymphocyte count) may provide added prognostic 
accuracy to the APACHE II (and possibly the APACHE III) system. This 
deserves to be studied, particularly in regard to HIV-positive patients with 
pneumonia whose APACHE II scores fall in the low range of the distribution. 
In conclusion, our results indicate that the APACHE II prognostic 
scoring system is not an accurate method of stratifying HIV-positive MICU 
patients with pneumonia (particularly NPCP) in respect to in-hospital 
mortality. When applied to HIV-positive patients without a diagnosis of 
pneumonia, however, APACHE II proved to be an accurate method of 
estimating mortality and risk adjustment. The reason for APACHE IPs 
underestimation of mortality is multifactorial. It is likely to be due, at least 
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partially, to (1) inadequate adjustment for the severity of immunologic 
suppression in patients with a diagnosis indicating an infectious etiology of 
their illness; (2) lack of precisely defined decisionmaking algorithms to aid in 
the assignment of disease categories; and (3) a significant proportion of HIV¬ 
positive patients with pneumonia of unknown etiology who may be 
uniquely resistant to treatment. The use of TLC as an additional risk factor 
may improve predictive accuracy of ICU risk adjustment models for use in 































Figure 4: Location prior to MICU 

Figure 5: Diseases Precipitating MICU Admission 











Figure 6: Distribution of APACHE SI Scores 











Figure 7 Receiver Operator Characteristics Curve 
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Figure 8: Estimated vs. Observed Mortality 
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Figure 9: Pathogens Causing Respiratory Infection 
in HIV-Positive Patients Admitted to MICU 
| No organism identified 
553 P. carinii 
II P. carinii plus others 
E3 Single organism, not P. carinii 
□ Polymicrobial, not P. carinii 
4 3% 

Figure 10: Estimated vs. Observed IVlortaSity Rates 
APACHE IS Scores 

Figure 11: Estimated vs. Observed Mortality Rates, 
Excluding Patients with Pneumonia 

Figure 12: Estimated vs. Observed Mortality Rates 
in Patients with Pneumonia 
APACHE !l Scores 

Table 7: Population Demographics: Sex, Race, and HIV Risk Factors 
HIV Risk Men 
Factor _(N=118)_ 
B H W NA 
Women 
(N=43) 
B H W 
IVDA* (N=98) 45 8 
Homosexual 
Activity** (N=25) 5 1 
Both+ (N=9) 7 1 





20 2 9 
0 0 0 
0 0 0 
10 1 1 
History of intravenous drug abuse, no history of homosexual activity 
History of homosexual activity, no history of IVDA 
’*’ History of both IVDA and homosexual activity 




NA= Native American 

Table 8: APACHE II's Accuracy in Outcome Prediction and Statistical Power 
Cutoff Point Sensitivity* Specificity* PPV* NPV* % Co 
> .10 94.4 24.4 49.6 84.6 55.2 
> .20 80.3 46.6 54.3 75.0 61.4 
> .30 66.2 70.0 63.5 72.4 66.4 
> .35 57.7 77.8 67.2 70.0 68.9 
> .40 53.5 80.0 67.8 68.6 68.3 
> .45 53.5 81.1 69.1 68.9 68.9 
> .50 43.7 85.5 70.5 65.8 67.1 
> .60 36.6 92.2 78.8 64.8 67.7 
> .70 26.8 93.3 76.0 61.7 64.0 
>.80 18.3 98.9 92.9 60.5 63.4 
> .90 9.9 100 100 57.0 58.3 
All numbers are percentages 

Table 9: Estimated vs. Observed Mortality by Disease Category 




Mortality (%) X2 
p value 
(d.f.= 1) 
All 161 35.5 44.1 5.19 < .025 
Pneumonia 44 28.5 50.0 9.98 < .005 
Not Pneumonia 117 38.1 41.9 .709 NS 
Sepsis 29 56.4 41.3 2.67 NS 
Pneumonia or Sepsis 73 39.6 46.6 1.48 NS 
Neither Pneumonia 
nor Sepsis 88 32.2 37.5 1.13 NS 

Table 10 A: Accuracy of Sputum Stain and Culture for the Identification of 
Pathogens in HIV-Positive Patients with Pneumonia 
Sputum 
test results 
Pathogen No pathogen 
identified ever identified 
Positive 17* 0 
Negative 20 7 
* A- 
Sensitivity= 17/37= 46% 
Negative Predictive Value= 7/27= 26% 
False Negative Rate= 20/27= 74% 
For the calculation of sensitivity, all positive sputum cultures/stains are assumed to be 
accurate. 
** For the calculation of negative predictive value, patients who never had a pathogen 
identified were assumed to not be microbially infected. 
Table 10 B: Accuracy of Sputum Stain and Culture for the Identification of 




P. car in ii 
Positive 6 
Negative 20 
Sensitivity= 6/26= 23% 
P. carinii, if not documented by sputum sample, was later identified by bronchoalveolar 
lavage, open lung biopsy, or at autopsy. 







Mortality (%) X2 p value 
PCP 26 28.2 34.6 0.53 NS 
NPCP 18 28.9 72.2 16.45 < .005 
PCP= Pneumocystis cnrinii pneumonia 
NPCP= Non-Pneumocystis carinii pneumonia 
Table 11 B: Estimated vs. Observed Mortality for Patients with Pneumonia 
Type of Estimated Observed 





PCP ■26 28.2 34.6 0.53 NS 
Other pathogen 11 23.2 63.6 _* = .005 
No pathogen 
identified 7 37.8 85.7 _* = .014 
PCP= Pneumocystis cnrinii pneumonia 
* Signifies that statistical significance was calcutated using a binomial 
distribution (1-tailed) 

Table 12: Estimated vs. Observed Mortality by APACHE II Scores 
Estimated Observed 
APACHE II Score N Mortality (%) Mortality (%) x2 p value 
All 161 35.5 44.1 5.19 < .025 
< 14 45 11.2 24.4 7.94 < .005 
15-19 43 24.2 37.2 3.97 < .05 
20 - 24 28 39.1 46.4 0.63 NS 
>25 45 68.5 68.9 .003 NS 

Table 13: Estimated vs. Observed Mortality by APACHE II Scores, Excluding 
Patients with Pneumonia 
Estimated Observed p value 
APACHE II Score N Mortality (%) Mortality (%) X2 (d.f.= 1) 
All 117 38.2 41.9 0.67 NS 
< 14 30 10.0 10.0 0.00 NS 
15-19 25 21.3 36.0 3.28 NS 
20-24 21 37.1 42.9 0.29 NS 
> 25 41 69.6 68.3 0.03 NS 

Table 14: Estimated vs. Observed Mortality by APACHE II Scores in Patients 
with Pneumonia 
Estimated Observed 
APACHE II Score N Mortality (%) Mortality (%) x2 p value 
All 44 28.5 50.0 9.98 < .005 
< 14 15 13.6 53.3 _* = .0002 
15-19 18 28.2 38.9 1.02 NS 
20-24 7 45.1 57.1 _* NS 
> 25 4 57.2 75.0 _* NS 
* Signifies that statistical significance was calculated using a binomial 
distribution (1-tailed) 

Table 15: APACHE II Scores for Survivors and Nonsurvivors 
Average APACHE II Scores ± S.D. 
Disease Category Survivors (N) Nonsurvivors (N) p value 
Pneumonia 16.5 ±4.5 (22) 17.5 ±5.9 (22) NS 
Not Pneumonia 17.3 ±6.9 (68) 26.3 ±10.3 (49) < .005 





PCP 17 9 65.4 
NPCP 5 13 27.8 
X2 = 6.018 p = 0.014 
Table 16 B: Mortality in Patients with PCP vs. Pneumonia of Unknown 
Etiology 
Observed 
Survivors Non-Survivors Survival (%) 
PCP 17 9 65.4 
Unknown etiology 1 6 14.3 
Fischer Exact test (2 tailed); p = .030 
Table 16 C: Mortality in Patients with Pneumonia, Excluding Patients 
without a Known Etiology of the Pneumonia 
Observed 
Survivors Non-Survivors Survival (%) 
PCP 17 9 65.4 
Other identified pathogen 4 7 36.4 
Fischer Exact test (2 tailed); p = .151 
PCP= Pneumocystis carinii pneumonia 
NPCP= Non-Pneumocystis carinii pneumonia 

Table 17: Severity of Illness in Patients with PCP vs. Non-PCP Pneumonia 
PCP (n=26) NPCP (n=18) p value 
Requiring 
Intubation (%) 85 83 NS 
Mean APACHE II 
Score 16.9 ±5.0 17.1 ±5.5 NS 
Predicted 
Mortality (%) 28.2 ± 13.8 28.9 ± 15.4 NS 
PCP - Pneumocystis carinii pneumonia 
NPCP =Non-Pneumocystis carinii pneumonia 

Table 18: Association between Total Lymphocyte Count (TLC)* and Mortality 
TLC # of Survivors # of Non-survivors 
< 200 14 
jf. 
A. Total Population 
22 Chi-square = 8.96 
>201 75 37 
p = .003 
<200 2 
B. Pneumonia or Sepsis 
12 Chi-square = 9.07 
>201 31 21 
p = .003 
<200 12 
C. Not Pneumonia nor Sepsis 
10 Chi-square = 2.62 
>201 44 16 
p = .105 
<200 1 
D. Pneumonia 
7 Fischer Exact (2-tailed) 
>201 19 13 
p = .048 
< 200 1 
E. Sepsis 
5 Fischer Exact (2-tailed) 
>201 12 8 
p = .163 
TLC was calculated using the formula TLC = # of WBC's x lymphocyte differential (% 
WBC's which were lymphocytes). 
3(* 
Of the total population of 161 patients, 148 (91.9%) had the necessary information in their 
charts for the calculation of TLC. 





Mortality (%) X- p value 
Emergency Room (n=81) 37.6 44.4 1.62 NS 
Hospital Floor (n=72) 33.3 44.4 4.02 < .05 

Table 20: Estimated vs. Observed Mortality by MICU Length of Stay 
Estimated Observed 
Mortality (%) Mortality (%) X2 p value 
MICU LOS < 14 days (n= 144) 34.9 40.3 1.83 NS 
MICU LOS > 14 days (n=l 7) 41.0 82.4 12.02 < .005 
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